![Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave | Nature Medicine Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-02138-x/MediaObjects/41591_2022_2138_Fig1_HTML.png)
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave | Nature Medicine
![Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | MMWR Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7104e4_OmicronTrends_IMAGE_25Jan2022_1200x675-medium.jpg?_=64254)
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | MMWR
![Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages — United States, January 2023 | MMWR Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages — United States, January 2023 | MMWR](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e3_CurrentVariants_Immunocompromised_IMAGE_27Jan2023_1200x675_1.jpg?_=59980)
Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages — United States, January 2023 | MMWR
![Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study - The Lancet Healthy Longevity Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study - The Lancet Healthy Longevity](https://www.thelancet.com/cms/asset/03ce445b-e741-4e68-bc7d-0d304a5b1ba7/gr1.jpg)